Eur Rev Med Pharmacol Sci 2022; 26 (19): 7125-7134
DOI: 10.26355/eurrev_202210_29898

The role of triglyceride-glucose index in determining subclinical atherosclerosis in patients with primary hypertension

O. Inan, E.S. Sahiner, I. Ates

Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey. drosmaninan@gmail.com


OBJECTIVE: With the current study, we aimed at examining the relationship between the triglyceride-glucose (TyG) index and subclinical atherosclerosis in patients with primary hypertension.

PATIENTS AND METHODS: 185 patients with primary hypertension were included in this study. The following findings were considered to be associated with target organ damage (TOD): urinary protein excretion > 150 mg/dL and microalbumin excretion > 30 mg/dL, carotid intima-media thickness (CIMT) ≥ 0.9 mm or carotid plaque and/or left ventricular mass index (LVMI) > 95 g/m2 in women, > 115 g/m2 in men.

RESULTS: TyG index values were positively correlated with levels of CIMT (r=0.434; p<0.001), LVMI (r=0.351; p<0.001), microalbuminuria (r=0.347; p<0.001), and proteinuria (r=0.355; p<0.001). In the multivariable regression model, in which the variables associated with the presence of TOD were included, increased age (OR: 1.04, p=0.025), increased body mass index (OR: 1.10, p=0.042), and increased TyG index value (OR: 1.05, p<0.001) had independent associations with TOD. The threshold value of the TyG index for the presence of TOD was determined as > 8.85 with 79.0% sensitivity and 77.1% specificity (AUC±SE: 0.859±0.03, +PV: 70.6%, -PV: 84.0%, p<0.001). The TyG index had a superior diagnostic discrimination compared to its components in predicting the presence of TOD.

CONCLUSIONS: Increased TyG index values in patients with primary hypertension are associated with damage to target organs, not merely subclinical atherosclerosis.

Free PDF Download

To cite this article

O. Inan, E.S. Sahiner, I. Ates
The role of triglyceride-glucose index in determining subclinical atherosclerosis in patients with primary hypertension

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 19
Pages: 7125-7134
DOI: 10.26355/eurrev_202210_29898